Cytosorbents’ (CTSO) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Cytosorbents (NASDAQ:CTSO) in a report published on Friday morning,Benzinga reports. They currently have a $10.00 target price on the medical research company’s stock.

Several other equities research analysts have also commented on CTSO. Wall Street Zen began coverage on Cytosorbents in a research note on Wednesday, May 21st. They set a “hold” rating for the company. HC Wainwright restated a “neutral” rating and set a $1.00 price target on shares of Cytosorbents in a research note on Thursday, May 15th.

Cytosorbents Stock Up 12.0%

CTSO opened at $1.00 on Friday. The company has a debt-to-equity ratio of 0.98, a quick ratio of 2.30 and a current ratio of 2.61. Cytosorbents has a one year low of $0.71 and a one year high of $1.61. The business’s fifty day moving average is $1.05 and its two-hundred day moving average is $1.03. The company has a market cap of $62.76 million, a price-to-earnings ratio of -5.88 and a beta of 1.19.

Cytosorbents (NASDAQ:CTSO) last issued its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.02. The business had revenue of $9.62 million for the quarter, compared to the consensus estimate of $9.79 million. Cytosorbents had a negative return on equity of 109.15% and a negative net margin of 25.58%. Analysts anticipate that Cytosorbents will post -0.3 EPS for the current fiscal year.

Institutional Trading of Cytosorbents

A number of hedge funds and other institutional investors have recently modified their holdings of CTSO. Millennium Management LLC acquired a new position in shares of Cytosorbents in the 4th quarter worth $30,000. Goldman Sachs Group Inc. grew its holdings in shares of Cytosorbents by 149.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company’s stock worth $63,000 after acquiring an additional 37,519 shares during the last quarter. Key Client Fiduciary Advisors LLC grew its holdings in shares of Cytosorbents by 127.0% in the 1st quarter. Key Client Fiduciary Advisors LLC now owns 78,457 shares of the medical research company’s stock worth $78,000 after acquiring an additional 43,900 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of Cytosorbents by 10.6% in the 4th quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company’s stock worth $80,000 after acquiring an additional 8,400 shares during the last quarter. Finally, Northern Trust Corp grew its holdings in shares of Cytosorbents by 22.3% in the 4th quarter. Northern Trust Corp now owns 91,560 shares of the medical research company’s stock worth $83,000 after acquiring an additional 16,701 shares during the last quarter. Institutional investors own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.